Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience

Table 3 Distribution of prostate cancer T stage before and after mpMRI of the prostate

	Initial clinical staging	Relative upstaging by mpMRI	Relative downstaging by mpMRI	mpMRI staging
T1–T2a ((very) low-risk)	53 (43.4%)	67.9%	n.a.	31 (19.4%)
T2b-c (intermediate-risk)	44 (36.1%)	36.4%	13.6%	49 (40.6%)
T3a-b ((very) high-risk)	25 (20.5%)	2.5%	36%	46 (37.7%)

T stage for the patients (n = 122) was attributed to specific risk groups according to the National Comprehensive Cancer Network prostate cancer guidelines. Initial clinical staging included digital rectal examination, ultrasound-guided transrectal biopsy as well as an abdominal and pelvic contrast-enhanced CT scan.

ISSN: 1748-717X